Histoplasmosis is a fungal infection resulting from inhalation of spores from the dimorphic fungus Histoplasma capsulatum; it is known to be endemic in various parts of the world, especially in North and Latin America, and can produce a spectrum of illness, from subclinical infection to progressive disseminated disease. The majority of infected persons have an asymptomatic, self-limiting illness. Clinical pneumonia occurs in those with exposure to a large number of infecting spores. Disseminated histoplasmosis usually occurs in immunosuppressed patients or in patients with chronic illness and is a serious opportunistic infection in patients with the acquired immunodeficiency syndrome (AIDS), often seen as the first manifestation of the syndrome. Diagnosis is best made by visualization of yeast in tissue or by culture. Treatment for disseminated histoplasmosis in patients with AIDS consists of two phases: initial induction therapy and subsequent lifelong maintenance therapy. In most cases amphotericin B is the initial drug of choice, followed by one of the azoles for lifelong maintenance therapy. Itraconazole is the drug of choice for treatment of disseminated histoplasmosis in less severe cases while fluconazole therapy for histoplasmosis is only moderately effective and should be reserved for patients who cannot take itraconazole.
|Translated title of the contribution||Histoplasma capsulatum infection in AIDS|
|Number of pages||5|
|Journal||Giornale Italiano di Malattie Infettive|
|Publication status||Published - 1998|
ASJC Scopus subject areas
- Microbiology (medical)